Articles By Jack Cush, MD
Shingles Vaccine Not Cost-Effective in Those Under 60
The herpes zoster (HZ- shingles) vaccine was FDA approved for use in individuals over age 50 years. However, the CDC Advisory Committee on Immunization Practices (ACIP) has recommended it only be used in those over age 60 years.
Read Article
Drug Safety Reports & FDA Updates – August 2015
Safety reports from literature include long-term safety of rituximab, rituximab-induced neutropenia, tabalumab (Anti-BAFF Mab) results from the ILLUMINATE trial, colchicine toxicity increased in CKD patients, FDA updates and drug labeling changes, and more.
Read Article
Serious Infections Increased in Etanercept-Treated Juvenile Arthritis Patients
UK researchers set out to study medically significant infections (MSI) in juvenile idiopathic arthritis patients enrolled in the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN).
Read Article
More Knee Replacements at Younger Ages
The National Hospital Discharge Survey shows that between 2000 and 2010, more than 5.2 million total knee replacements were performed in the United States. By 2010, the operation had become the leading inpatient surgery performed on adults aged 45 and over.
Read Article
SCOT Study Shows NSAID Safety
Since the 2005 FDA hearing that resulted in the removal of Vioxx and Bextra from the US market, the safety of nonselective NSAIDs (nsNSAIDs) and selective Cox-2 inhibitors (e.g., celecoxib) has been repeatedly questioned, often without new or substantive data.
Read Article
Hospitalized Infections are Higher with the Second Biologic
Using Medicare claims data on 189,326 RA patients, researchers at the University of Alabama at Birmingham examined the rates of hospitalized infections in previously biologic-treated RA patients and compared rates in cohorts starting new treatment with etanercept, adalimumab, certolizum
Read Article
Time to Listen
Every physician struggles with time and listening. Modern medicine infringes on both of these - and they may be the most humanistic things a physician can give.
Read Article
Romosozumab Surpasses Teraparitide in the STRUCTURE Study
The experimental bone drug, romosozumab, has succeeded in meeting its primary endpoint by showing it was significantly more effective than teriparatide in a 12-month study assessing total hip bone density in postmenopausal women with osteoporosis.
Read Article
Bicycle Injuries and Fatalities Increasing in Older Americans
JAMA reports the number of traumatic injuries related to bikes in adults nearly doubled from 1998 to 2013 -- going from 8,791 to 15,427. The researchers used data from the National Electronic Injury Surveillance System, which includes data from of 100 emergency departments, and U.S.
Read Article
Advances in Uveitis Associated with Juvenile Arthritis
Uveitis is a common association of juvenile idiopathic arthritis (JIA) that has previously been characterized by poor visual prognosis with limited options for effective treatment.
Read Article
